vs

Side-by-side financial comparison of Opus Genetics, Inc. (IRD) and Versus Systems Inc. (VS). Click either name above to swap in a different company.

Opus Genetics, Inc. is the larger business by last-quarter revenue ($3.9M vs $2.2M, roughly 1.8× Versus Systems Inc.).

Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.

Versus Systems Inc. operates a proprietary interactive reward platform that integrates with video games, streaming content, live sports broadcasts and mobile apps. It enables content creators and brands to offer personalized real-time prizes to audiences across North America and global digital entertainment markets.

IRD vs VS — Head-to-Head

Bigger by revenue
IRD
IRD
1.8× larger
IRD
$3.9M
$2.2M
VS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IRD
IRD
VS
VS
Revenue
$3.9M
$2.2M
Net Profit
$-964.9K
Gross Margin
0.2%
Operating Margin
-54.2%
Net Margin
-44.7%
Revenue YoY
-10.2%
Net Profit YoY
53.0%
-19.2%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRD
IRD
VS
VS
Q4 25
$3.9M
$2.2M
Q3 25
$3.1M
$0
Q2 25
$2.9M
$-176.0K
Q1 25
$4.4M
Q4 24
$4.3M
$0
Q3 24
$3.9M
Q2 24
$1.1M
Q1 24
$1.7M
Net Profit
IRD
IRD
VS
VS
Q4 25
$-964.9K
Q3 25
$-17.5M
$-537.8K
Q2 25
$-7.4M
$672.3K
Q1 25
$-8.2M
Q4 24
$-809.5K
Q3 24
$-7.5M
Q2 24
$-7.8M
Q1 24
$-7.1M
Gross Margin
IRD
IRD
VS
VS
Q4 25
0.2%
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
IRD
IRD
VS
VS
Q4 25
-54.2%
Q3 25
-269.9%
Q2 25
-309.0%
Q1 25
-227.2%
Q4 24
Q3 24
-207.1%
Q2 24
-748.9%
Q1 24
-450.5%
Net Margin
IRD
IRD
VS
VS
Q4 25
-44.7%
Q3 25
-566.9%
Q2 25
-257.5%
-382.0%
Q1 25
-187.5%
Q4 24
Q3 24
-194.6%
Q2 24
-698.3%
Q1 24
-415.3%
EPS (diluted)
IRD
IRD
VS
VS
Q4 25
Q3 25
$-0.25
Q2 25
$-0.12
$0.14
Q1 25
$-0.24
Q4 24
$-0.27
Q3 24
$-0.29
Q2 24
$-0.30
Q1 24
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRD
IRD
VS
VS
Cash + ST InvestmentsLiquidity on hand
$45.1M
$527.4K
Total DebtLower is stronger
Stockholders' EquityBook value
$15.3M
$10.2M
Total Assets
$50.2M
$2.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRD
IRD
VS
VS
Q4 25
$45.1M
$527.4K
Q3 25
$30.8M
Q2 25
$32.4M
Q1 25
$41.8M
Q4 24
$30.3M
$3.1M
Q3 24
$36.6M
Q2 24
$41.4M
Q1 24
$47.2M
Stockholders' Equity
IRD
IRD
VS
VS
Q4 25
$15.3M
$10.2M
Q3 25
$6.0M
$11.1M
Q2 25
$17.5M
$11.7M
Q1 25
$5.1M
Q4 24
$6.7M
$11.4M
Q3 24
$34.3M
Q2 24
$40.6M
Q1 24
$46.1M
Total Assets
IRD
IRD
VS
VS
Q4 25
$50.2M
$2.1M
Q3 25
$36.1M
$3.1M
Q2 25
$38.7M
$3.8M
Q1 25
$48.2M
Q4 24
$36.9M
$3.5M
Q3 24
$40.4M
Q2 24
$44.8M
Q1 24
$51.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRD
IRD
VS
VS
Operating Cash FlowLast quarter
$-35.3M
$-568.6K
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRD
IRD
VS
VS
Q4 25
$-35.3M
$-568.6K
Q3 25
$-6.2M
$24.7K
Q2 25
$-10.3M
$-867.5K
Q1 25
$-9.0M
Q4 24
$-25.6M
$-716.6K
Q3 24
$-5.1M
Q2 24
$-7.3M
Q1 24
$-5.7M
Cash Conversion
IRD
IRD
VS
VS
Q4 25
Q3 25
Q2 25
-1.29×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons